Lê M G
Epidémiologiste INSERM Unité 351. Institut Gustave-Roussy, Villejuif.
J Gynecol Obstet Biol Reprod (Paris). 1996;25(7):684-7.
Therapeutic trials comparing hormonal replacement therapy (HRT) with a placebo are rare and bring up non conclusive results. The last meta-analysis reported included 31 non randomized studies. It did not show an increased risk of breast cancer in women treated with HRT, compared with untreated women. However, on and after the 10th year of use, the risk increased significantly, although only slightly. This increase of the risk was restricted to the current users of HRT. The three studies published after the meta-analysis showed controversial results, and did not allow any conclusion. These wide disparities between the studies have highlighted the difficulty in interpreting the results of epidemiological studies.
比较激素替代疗法(HRT)与安慰剂的治疗试验很少,且结果尚无定论。最近报道的一项荟萃分析纳入了31项非随机研究。与未接受治疗的女性相比,该分析未显示接受HRT治疗的女性患乳腺癌的风险增加。然而,在使用HRT的第10年及之后,风险虽仅略有上升,但显著增加。这种风险增加仅限于HRT的当前使用者。荟萃分析之后发表的三项研究结果存在争议,无法得出任何结论。这些研究之间的巨大差异凸显了解读流行病学研究结果的困难。